These findings corroborate previous results obtained in animal models, highlighting the specific expression pattern of the MIF-CD44 axis and its associated spatial distribution in liver metastasis patients with concurrent MASLD, making it a promising target for tailored interventions in the context of PDAC, suggesting that inhibition of MIF-CD44 axis has translational potential. The gene discussed is CD44; the disease is metabolic dysfunction-associated steatotic liver disease.